Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of one of the following: Non-Hodgkin's lymphoma Primary or metastatic solid tumor located, by radiography, in at least one of the following sites: Liver Soft tissue Pelvis Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field) Relapsed or refractory (including unresectable) disease Patients with solid tumors must have failed all curative chemotherapeutic regimens Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab Not amenable to available conventional therapies AND no standard therapy exists Measurable disease No prior or concurrent CNS metastases (brain or leptomeningeal) No primary intracranial tumor by MRI or CT scan No histologically confirmed squamous cell carcinoma of the lung PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 Life expectancy Not specified Hematopoietic WBC ≥ 3,500/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 No severe or uncontrolled hematologic condition Hepatic Bilirubin ≤1.5 times upper limit of normal (ULN) AST and ALT ≤ 2.5 times ULN PT and PTT normal INR normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine ≤ ULN Urine protein/creatinine ratio ≤ 1 No severe or uncontrolled renal condition Cardiovascular No clinically significant acute electrocardiographic abnormalities LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines No untreated or uncontrolled hypertension No blood pressure > 150/100 mm Hg (despite treatment) No isolated systolic hypertension (i.e., systolic blood pressure > 180 mm Hg on at least 2 determinations [on separate days] within the past 3 months) No New York Heart Association class II - IV heart disease No active coronary artery disease requiring acute medical management No angina requiring acute medical management No congestive heart failure requiring acute medical management No ventricular arrhythmia requiring acute medical management No stroke or transient ischemic event within the past 6 months No prior or concurrent peripheral vascular disease No angiographically or ultrasonographically documented arterial or venous occlusive event No symptomatic claudication No symptomatic orthostatic hypotension No other severe or uncontrolled cardiovascular condition Pulmonary No severe or uncontrolled pulmonary condition No pulmonary embolism within the past 6 months Immunologic HIV negative No severe or uncontrolled immunologic condition No active current infection requiring antibiotics No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap Other No severe or uncontrolled gastrointestinal or musculoskeletal condition No psychiatric condition or adverse social circumstance that would preclude study participation No other condition that would preclude study participation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial At least 3 weeks since prior immunotherapy and recovered No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF) Chemotherapy See Disease Characteristics At least 3 weeks since prior chemotherapy and recovered Endocrine therapy No concurrent adrenal corticosteroids except low-dose replacement therapy No concurrent systemic hormonal contraceptive agents Radiotherapy At least 3 weeks since prior radiotherapy and recovered Surgery At least 3 weeks since prior major or laparoscopic surgery and recovered More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events Other More than 30 days since prior investigational drugs No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access devices No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors No other concurrent anticancer investigational agents No other concurrent anticancer therapy